Business · Companies · 1 hr ago

Samsung Biologics raises 2.665 trillion won in share sale

Samsung Biologics raises 2.665 trillion won in share sale

Samsung Biologics raised 2.665 trillion won through a share sale in South Korea.

Investors placed orders for more than 11.4 trillion won of the shares left after existing shareholders and employees had a chance to buy.

That demand meant the remaining shares were oversubscribed 135.6 times.

A rights issue lets a company raise money by issuing new shares, and Samsung Biologics plans to use the funds to speed up its planned acquisition of PolyPeptide Group.

The Swiss company makes peptide medicines, including products linked to the growing market for GLP-1 weight-loss treatments.

The share sale’s remaining steps are due on Nov.

17 for payment and Nov.

30 for listing.

1 source

Related

What people are saying

Samsung BiologicsCompany
The largest ever among rights offerings that included a public offering
via Yonhap